Body mass index and exon 19 mutation as factors predicting the therapeutic efficacy of gefitinib in patients with epidermal growth factor receptor mutation‐positive non‐small cell lung cancer

摘要

BackgroundMany randomized clinical trials have demonstrated that epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs) are advantageous over standard chemotherapy, either as front‐line treatment or as further management of patients with EGFR mutation‐positive non‐small‐cell lung cancer (NSCLC). However, which subgroup of these patients could benefit more from EGFR‐TKIs needs to be further explored. In the present study, we explored the predictive factors in such cohorts of patients who received gefitinib.